Novo Nordisk


Zuellig Pharma
Concise Prescribing Info
Adult w/ type 2 DM in combination w/ metformin &/or sulfonylurea, metformin & thiazolidinedione or combination therapy w/ metformin & insulin in patient w/ insufficient glycaemic control. Reduction of major adverse CV events (MACE) eg, CV death, non-fatal MI & stroke in adults w/ type 2 diabetes who have established or at high risk for CV disease.
Dosage/Direction for Use
SC Initially 0.6 mg daily, may be increased to 1.2 mg after at least 1 wk. Max: 1.8 mg daily.
May be taken with or without food.
Special Precautions
Not to be inj IV or IM. Not to be used in type 1 DM or diabetic ketoacidosis. Not an insulin substitute. Not recommended in CHF NYHA class IV, inflammatory bowel disease, diabetic gastroparesis. Discontinue use if acute pancreatitis occur. Preexisting thyroid disease, hypoglycaemia. Ensure adequate fluid intake. May affect ability to drive & use machines. Not recommended in end-stage renal disease or severe hepatic impairment. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr.
Adverse Reactions
Nausea, diarrhoea. Nasopharyngitis, bronchitis; hypoglycaemia, anorexia, decreased appetite; headache, dizziness; increased heart rate; vomiting, dyspepsia, upper abdominal pain, constipation, gastritis, flatulence, abdominal distension & discomfort, GERD, toothache; rash; fatigue, inj site reactions; increased lipase & amylase.
Drug Interactions
Frequent monitoring of INR w/ warfarin & other coumarin derivatives.
MIMS Class
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Victoza soln for inj 6 mg/mL
3 mL x 2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in